In addition, there was a highly significant reduction of [ 18 F]Tz binding to A549-PDL1 cells when durvalumab/atezolizumab-TCO binding was prevented by presaturation of receptors using unmodified anti-PD-L1 antibody or under competition with a large excess of nonlabeled tetrazine ( Figure 2 A,B).
← all excerpts
Bioorthogonal Diels-Alder Click Chemistry-Based Pretargeted PET Imaging Strategy for Monitoring Programmed Death-Ligand 1 Expression.
1
—
—